The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study.

Cancer Med · 2023 · PMC10587943 · PMID 37723846

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

not significantly significantno p-value reported

PFS was slightly longer in patients initially diagnosed with EGFR 21 L858R than with EGFR 19 Del (median PFS 3.1 and 1.6 months, HR 0.579, 95% CI 0.209–1.605), but the difference was not significantly significant.

also in 164 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.